11-beta-hydroxylase Inhibitors
1 drugsAbout 11-beta-hydroxylase
11-beta-hydroxylase (CYP11B1) is an enzyme essential for synthesizing cortisol and aldosterone, hormones regulating stress response, blood pressure, and electrolyte balance.
As a modulator of steroid hormones, 11-beta-hydroxylase is a potential drug target; however, there is currently no genetic evidence linking it to specific diseases.
METOPIRONE, a small molecule, is the only FDA-approved drug targeting 11-beta-hydroxylase, approved in 1961 and marketed by ESTEVE for one indication.
Top 11-beta-hydroxylase Drugs
ESTEVE is the only company with an approved drug targeting 11-beta-hydroxylase.
Low competition suggests an opportunity, but also a potential lack of market validation.
11-beta-hydroxylase Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets 11-beta-hydroxylase, using small molecule modality.
Explore alternative modalities like antibodies or peptides to differentiate from existing therapies.
11-beta-hydroxylase Clinical Trials 8 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on 11-beta-hydroxylase. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 2 | 2 | 0 | 0 | 100% |
| Phase 2 | 2 | 0 | 0 | 2 | - |
| Phase 3 | 2 | 2 | 0 | 0 | 100% |
| Phase 4 | 2 | 0 | 0 | 2 | - |
Top Sponsors
By Modality
Top Conditions
Top Drugs
11-beta-hydroxylase Drug Approval Timeline (1961 - 1961)
METOPIRONE was approved in 1961 and no new drugs have been approved since.
The long approval gap indicates potential challenges or lack of interest in this target.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 7 (2 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on 11-beta-hydroxylase. A trial counts if an approved drug acting on 11-beta-hydroxylase is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.